PRGs serve as potential biomarkers for the immune infiltration of glioma and may exert inhibitory or promotional effects on cancer-associated signaling pathways through the modulation of protein palmitoylation, thereby implying their potential as therapeutic targets in glioma treatment. Here, GART is linked to central nervous system cancer.